Rockefeller Capital Management L.P. Makes New Investment in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Rockefeller Capital Management L.P. acquired a new position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 11,034 shares of the medical equipment provider's stock, valued at approximately $1,167,000.

Other institutional investors have also recently made changes to their positions in the company. Sterling Capital Management LLC increased its holdings in Zimmer Biomet by 18.3% in the fourth quarter. Sterling Capital Management LLC now owns 16,403 shares of the medical equipment provider's stock valued at $1,733,000 after buying an additional 2,535 shares in the last quarter. Heritage Trust Co purchased a new position in shares of Zimmer Biomet in the 4th quarter valued at about $1,938,000. Kennedy Capital Management LLC raised its holdings in Zimmer Biomet by 26.1% in the 4th quarter. Kennedy Capital Management LLC now owns 31,426 shares of the medical equipment provider's stock worth $3,320,000 after purchasing an additional 6,505 shares during the period. Bessemer Group Inc. boosted its position in Zimmer Biomet by 6.0% during the fourth quarter. Bessemer Group Inc. now owns 3,025 shares of the medical equipment provider's stock worth $320,000 after purchasing an additional 171 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in Zimmer Biomet in the fourth quarter valued at approximately $21,234,000. 88.89% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on ZBH. Truist Financial reiterated a "hold" rating and set a $113.00 target price (down previously from $118.00) on shares of Zimmer Biomet in a research report on Monday, February 10th. Raymond James cut their target price on shares of Zimmer Biomet from $126.00 to $119.00 and set an "outperform" rating for the company in a research note on Friday, February 7th. Needham & Company LLC reaffirmed a "hold" rating on shares of Zimmer Biomet in a research note on Friday, February 7th. BTIG Research reiterated a "buy" rating on shares of Zimmer Biomet in a research note on Monday, April 14th. Finally, Royal Bank of Canada decreased their target price on Zimmer Biomet from $130.00 to $125.00 and set an "outperform" rating on the stock in a research report on Friday, February 7th. Two research analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have given a buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $124.15.

Zimmer Biomet Trading Down 0.0 %

NYSE ZBH traded down $0.04 during trading hours on Friday, reaching $101.46. The company had a trading volume of 1,661,962 shares, compared to its average volume of 1,667,422. Zimmer Biomet Holdings, Inc. has a 1-year low of $93.10 and a 1-year high of $123.96. The stock has a market capitalization of $20.07 billion, a P/E ratio of 22.80, a price-to-earnings-growth ratio of 1.95 and a beta of 0.84. The stock has a 50-day moving average of $105.81 and a 200 day moving average of $106.56. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, topping analysts' consensus estimates of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same quarter in the previous year, the company posted $2.20 earnings per share. As a group, research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be given a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 0.95%. The ex-dividend date is Monday, March 31st. Zimmer Biomet's dividend payout ratio is currently 21.57%.

Insiders Place Their Bets

In related news, SVP Lori Winkler sold 1,443 shares of Zimmer Biomet stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total value of $150,649.20. Following the completion of the transaction, the senior vice president now owns 8,768 shares in the company, valued at approximately $915,379.20. The trade was a 14.13 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.70% of the company's stock.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.